AMRX
Price:
$8.405
Market Cap:
$2.60B
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, p...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2018-05-07
Stock Exchange
NYSE
Ticker
AMRX
According to Amneal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 5.28B. This represents a change of 26.31% compared to the average of 4.18B of the last 4 quarters.
The mean historical Enterprise Value of Amneal Pharmaceuticals, Inc. over the last ten years is 3.38B. The current 5.28B Enterprise Value has changed 15.55% with respect to the historical average. Over the past ten years (40 quarters), AMRX's Enterprise Value was at its highest in in the September 2018 quarter at 5.44B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.
Average
3.38B
Median
3.30B
Minimum
0
Maximum
8.02B
Discovering the peaks and valleys of Amneal Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Enterprise Value = 8.02B
Minimum Annual Increase = -81.37%
Minimum Annual Enterprise Value = 0
Year | Enterprise Value | Change |
---|---|---|
2023 | 3.73B | 19.51% |
2022 | 3.12B | -6.65% |
2021 | 3.34B | 2.09% |
2020 | 3.27B | 0.67% |
2019 | 3.25B | -22.58% |
2018 | 4.20B | 26.38% |
2017 | 3.32B | 122.34% |
2016 | 1.49B | -81.37% |
2015 | 8.02B | Infinity% |
The current Enterprise Value of Amneal Pharmaceuticals, Inc. (AMRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.40B
5-year avg
3.34B
10-year avg
3.38B
Amneal Pharmaceuticals, Inc.’s Enterprise Value is greater than Alkermes plc (4.20B), less than Neurocrine Biosciences, Inc. (12.09B), less than Intra-Cellular Therapies, Inc. (8.69B), greater than Deciphera Pharmaceuticals, Inc. (2.15B), greater than Dynavax Technologies Corporation (1.69B), greater than Amphastar Pharmaceuticals, Inc. (2.89B), greater than Collegium Pharmaceutical, Inc. (1.44B), greater than Ironwood Pharmaceuticals, Inc. (1.20B), greater than ANI Pharmaceuticals, Inc. (1.25B), greater than Phibro Animal Health Corporation (1.36B), greater than Procaps Group S.A. (473.19M), greater than Silver Spike Investment Corp. (33.56M), greater than Eagle Pharmaceuticals, Inc. (16.86M), greater than Evolus, Inc. (1.07B), greater than Agile Therapeutics, Inc. (7.87M), greater than Assertio Holdings, Inc. (96.97M), greater than AcelRx Pharmaceuticals, Inc. (1.19M), greater than Lifecore Biomedical, Inc. (343.00M),
Company | Enterprise Value | Market cap |
---|---|---|
4.20B | $4.30B | |
12.09B | $12.19B | |
8.69B | $9.14B | |
2.15B | $2.21B | |
1.69B | $1.55B | |
2.89B | $2.46B | |
1.44B | $1.05B | |
1.20B | $668.51M | |
1.25B | $1.18B | |
1.36B | $906.84M | |
473.19M | $200.83M | |
33.56M | $66.72M | |
16.86M | $9.72M | |
1.07B | $1.03B | |
7.87M | $10.43M | |
96.97M | $101.06M | |
1.19M | $14.58M | |
343.00M | $220.59M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amneal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Amneal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Amneal Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Amneal Pharmaceuticals, Inc. (AMRX)?
What is the 3-year average Enterprise Value for Amneal Pharmaceuticals, Inc. (AMRX)?
What is the 5-year average Enterprise Value for Amneal Pharmaceuticals, Inc. (AMRX)?
How does the current Enterprise Value for Amneal Pharmaceuticals, Inc. (AMRX) compare to its historical average?